Peninsula Pharmaceuticals Report issue

Contributed to NME For profit Phase 3
Founded: Alameda CA United States (2001)
Status: Acquired by Johnson and Johnson (2005)

Organization Overview

First Clinical Trial
2003
NCT00229021
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2004

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Peninsula Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

doripenem (doribax) (6 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acalculous Cholecystitis (Phase 3)

Appendicitis (Phase 3)

Bacterial Infections (Phase 3)

Cholecystitis (Phase 3)

Communicable Diseases (Phase 3)

Healthcare-Associated Pneumonia (Phase 3)

Infections (Phase 3)

Intraabdominal Infections (Phase 3)

Mycoses (Phase 3)

Pancreatitis (Phase 3)

Peritonitis (Phase 3)

Pneumonia (Phase 3)

Pneumonia, Ventilator-Associated (Phase 3)

Pyelonephritis (Phase 3)

Urinary Tract Infections (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 1